Last Updated: June 24, 2026

PSORCON E Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Psorcon E patents expire, and when can generic versions of Psorcon E launch?

Psorcon E is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in PSORCON E is diflorasone diacetate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Psorcon E

A generic version of PSORCON E was approved as diflorasone diacetate by AVONDALE PHARMS on April 27th, 1999.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for PSORCON E?
  • What are the global sales for PSORCON E?
  • What is Average Wholesale Price for PSORCON E?
Summary for PSORCON E
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 56
Patent Applications: 6,326
DailyMed Link:PSORCON E at DailyMed

US Patents and Regulatory Information for PSORCON E

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer PSORCON E diflorasone diacetate OINTMENT;TOPICAL 017994-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PSORCON E

See the table below for patents covering PSORCON E around the world.

Country Patent Number Title Estimated Expiration
Argentina 197216 PROCEDIMIENTO PARA PRODUCIR 17,21-DIACETATO DE 6ALPHA,9ALPHA-DIFLUORO-11BETA,17,21-TRIHIDROXI-16BETA-METIL-PREGNA-1,4-DIEN-3,20-DIONA ⤷  Start Trial
Australia 468257 ⤷  Start Trial
Australia 5257973 ⤷  Start Trial
Belgium 796560 ⤷  Start Trial
Belgium 821496 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.